A new thiadiazine derivative induces oxidative stress dependent JNK pathway activation and cell death in hepatocellular carcinoma

Date

2019-07-01

Author

Kahraman, Deniz Cansen
TOZKOPARAN KÖPRÜCÜ, BİRSEN
Atalay, Rengül

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

184
views

0
downloads

Hepatocellular carcinoma (HCC) is the fifth most common and the second lethal cancer worldwide. HCC is resistant to conventional chemotherapy and radiotherapy due to its highly heterogenous structure. Therefore, it is crucial to design and develop novel therapeutic strategies against HCC. Non-steroidal anti-inflammatory drugs (NSAIDs) have long been studied for the treatment of acute and chronic conditions with pain and inflammation. In recent years, evidence from various studies suggested that NSAIDs reduce the incidence and mortality of various types of cancers. Here, investigated the possible cytotoxic bioactivities of a series of triazolothiadiazine derivatives on HCC cells, which have been previously reported as potent analgesic/anti-inflammatory compounds. For this purpose, we first investigated the anticancer effect of our compounds bearing a triazolothiadiazine core. Initially, 30 compounds were tested against cancer cells. Among all the compounds, three of them (7a, 7b and 7c) showed noticeable cytotoxic activities within µM concentrations and were selected to be screened against a panel of HCC cell lines. Compound 7b was identified as a promising anti-cancer agent against liver cancer cells with cytotoxic doses (less than 5µM) assessed by both the SRB assay and RT-CES analysis and was analyzed with further in vitro and in vivo experiments to disclose the underlying mechanism of its action in HCC cells. Time- and dose- dependent growth inhibition upon treatment with compound 7b was observed due to cell cycle arrest at the G2/M phase and apoptosis. After detecting the activation of SAPK/JNK pathway, it was shown that ROS accumulation was triggering the downstream events and eventually apoptotic cell death. Furthermore, upon treatment with compound 7b, overall survival of xenografts increased, while the tumor size decreased compared to control groups. Additionally, we investigated the potential of this compound on liver cancer stem cell population (CD133+/EpCAM+) which are known to be responsible for drug resistance in HCC. Compound 7b was bioactive against LCSCs and decreased the ratio of CD133+/EpCAM+ population significantly in both Huh7 and Mahlavu cells. Altogether, the anti-tumor and anti-resistance effects of compound 7b approves that this small molecule can be considered as an anti-cancer agent for liver cancer therapeutics.

Subject Keywords

Oncology

URI

https://hdl.handle.net/11511/32330

DOI

https://doi.org/10.1158/1538-7445.sabcs18-995

Collections

Graduate School of Informatics, Conference / Seminar

Suggestions

OpenMETU
Core

A small library of chalcones induce liver cancer cell death through Akt phosphorylation inhibition Sahin, Irem Durmaz; Christodoulou, Michael S.; Guzelcan, Ece Akhan; Koyas, Altay; Karaca, Cigdem; Passarella, Daniele; Atalay, Rengül (Springer Science and Business Media LLC, 2020-7-16) Hepatocellular carcinoma (HCC) ranks as the fifth most common and the second deadliest cancer worldwide. HCC is extremely resistant to the conventional chemotherapeutics. Hence, it is vital to develop new treatment options. Chalcones were previously shown to have anticancer activities in other cancer types. In this study, 11 chalcones along with quercetin, papaverin, catechin, Sorafenib and 5FU were analyzed for their bioactivities on 6 HCC cell lines and on dental pulp stem cells (DPSC) which differentiate...
Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells Karaosmanoglu, Oguzhan; Banerjee, Sreeparna; SİVAS, HÜLYA (Springer Science and Business Media LLC, 2018-08-01) Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Complete epithelial to mesenchymal transition (EMT) has long been considered as a crucial step for metastasis initiation. It has, however, become apparent that many carcinoma cells can metastasize without complete loss of epithelial traits or with incomplete gain of mesenchymal traits, i.e., partial EMT. Here, we aimed to determine the similarities and differences between complete and partial EMT through over-expr...
A new triazolothiadiazine derivative inhibits stemness and induces cell death in HCC by oxidative stress dependent JNK pathway activation Kahraman, Deniz Cansen; Guven, Ebru Bilget; Aytac, Peri S.; Aykut, Gamze; Tozkoparan, Birsen; Atalay, Rengul Cetin (2022-09-01) Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer, and resistant to both conventional and targeted chemotherapy. Recently, nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to decrease the incidence and mortality of different types of cancers. Here, we investigated the cellular bioactivities of a series of triazolothiadiazine derivatives on HCC, which have been previously reported as potent analgesic/anti-inflammatory compounds. From the initially tested 32 triazolothiadiazine NSAI...
15-Lipoxygenase-1 expression suppresses the invasive properties of colorectal carcinoma cell lines HCT-116 and HT-29. Cimen, I; Tunçay, S; Banerjee, Sreeparna (Wiley, 2009-12-01) Colorectal carcinoma (CRC) is often lethal when invasion and/or metastasis occur. 15-Lipoxygenase-1 (15-LO-1), a member of the inflammatory eicosanoid pathway, oxidatively metabolizes linoleic acid and its expression is repressed in CRC. In this study, we investigated the hypothesis that the lack of 15-LO-1 expression in CRC cells might contribute to tumorigenesis. Therefore we introduced 15-LO-1 into HCT-116 and HT-29 cells that do not have detectable levels of 15-LO-1. Our data indicate that expression of...
Monoclonal antibodies for targeted therapy in colorectal cancer. Banerjee, Sreeparna (Informa UK Limited, 2010-04-15) Traditional therapeutic regimens of solid tumors such as chemotherapy and radiotherapy often do not distinguish between malignant and normal tissues, resulting in considerable side-effects. Monoclonal antibodies (mAbs), targeted against antigens dysregulated in cancers, have therefore generated great interest in both clinical and research settings. The antibodies are either chimeric or human(ized) and can bind to and inhibit target proteins overexpressed in both solid tumors and hematological malignancies. ...

Citation Formats

D. C. Kahraman, B. TOZKOPARAN KÖPRÜCÜ, and R. Atalay, “A new thiadiazine derivative induces oxidative stress dependent JNK pathway activation and cell death in hepatocellular carcinoma,” 2019, vol. 79, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/32330.